Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events
- PMID: 23591024
- DOI: 10.1097/MJT.0b013e31827c5372
Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events
Abstract
Existing epidemiologic and clinical trial data suggest that the blood pressure in patients with hypertension at high risk for cardiovascular events because of coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, or heart failure should be reduced to <140/90 mm Hg in patients younger than 80 years and the systolic blood pressure be reduced to 140-145 mm Hg if tolerated in patients aged 80 years and older. Studies from patients with coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, and heart failure will be discussed that support a blood pressure goal of <140/90 mm Hg in patients younger than 80 years at high risk for cardiovascular events.
Similar articles
-
What should the blood pressure goal be in patients with hypertension who are at high risk for cardiovascular disease?Hosp Pract (1995). 2012 Oct;40(4):28-32. doi: 10.3810/hp.2012.10.1000. Hosp Pract (1995). 2012. PMID: 23299033
-
Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population?J Am Soc Hypertens. 2014 Jul;8(7):491-7. doi: 10.1016/j.jash.2014.04.010. Epub 2014 May 5. J Am Soc Hypertens. 2014. PMID: 25064771
-
Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.J Am Coll Cardiol. 2014 Dec 2;64(21):2196-203. doi: 10.1016/j.jacc.2014.09.022. Epub 2014 Nov 19. J Am Coll Cardiol. 2014. PMID: 25447261
-
[Hypertension as a function of age].Ital Heart J. 2000 Jun;1 Suppl 2:23-31. Ital Heart J. 2000. PMID: 10905125 Review. Italian.
-
How early should blood pressure control be achieved for optimal cardiovascular outcomes?J Hum Hypertens. 2011 Apr;25(4):211-7. doi: 10.1038/jhh.2010.64. Epub 2010 Jul 1. J Hum Hypertens. 2011. PMID: 20596060 Review.
Cited by
-
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.Int J Clin Oncol. 2023 Sep;28(9):1183-1190. doi: 10.1007/s10147-023-02364-4. Epub 2023 Jun 15. Int J Clin Oncol. 2023. PMID: 37322220
-
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2014 Feb;70(2):225-31. doi: 10.1007/s00228-013-1598-1. Epub 2013 Oct 23. Eur J Clin Pharmacol. 2014. PMID: 24150533
-
Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.Support Care Cancer. 2022 Dec;30(12):10203-10211. doi: 10.1007/s00520-022-07381-z. Epub 2022 Oct 11. Support Care Cancer. 2022. PMID: 36217043
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical